Literature DB >> 8472354

Increased urinary excretion of pyridinium cross-links in cancer patients.

A Lipton1, L Demers, Y Daniloff, E Curley, C Hamilton, H Harvey, L Witters, J Seaman, R Van der Giessen, S Seyedin.   

Abstract

Pyridinoline (PYD) and deoxypyridinoline (DPD), two collagen-based cross-links found in bone, were measured by high-performance liquid chromatography in urine samples from 65 control subjects and 97 patients with either untreated or progressive cancer. Patients with cancer had significantly (P < 0.001) higher urine concentrations of PYD and DPD than did control subjects. Both cross-links were increased in cancer patients with and without clinically detectable bone metastases, although patients with bone and liver involvement had higher mean concentrations. The mean concentrations of both cross-links were also significantly higher in the urine samples of inpatients than in an outpatient ambulatory population. These findings suggest that the measurement of PYD and DPD in urine may be useful in assessing bone metastases and bone resorption in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472354

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.

Authors:  Motohiro Tamiya; Hidekazu Suzuki; Masashi Kobayashi; Shinji Sasada; Norio Okamoto; Naoko Morishita; Tomomi Yasue; Yuka Matsuura; Tomonori Hirashima; Ichiro Kawase
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

2.  Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.

Authors:  J J Body; J C Dumon; E Gineyts; P D Delmas
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Metabolic effects of pamidronate in patients with metastatic bone disease.

Authors:  J Vinholes; C Y Guo; O P Purohit; R Eastell; R E Coleman
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.